MedTrace Logo

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

NCT04149860 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety of a single dose of Lu AF87908, how well it is tolerated and what the body does to the drug in healthy participants and participants with Alzheimer's disease.

Conditions

  • Healthy
  • Alzheimer Disease

Interventions

DRUG

Lu AF87908

Lu AF87908 concentrate for solution for intravenous (IV) infusion

DRUG

Placebo

Concentrate for solution for IV infusion

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2023-07-19
Completion
2023-07-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04149860 on ClinicalTrials.gov